Phaseline

Companies › Albireo, an Ipsen Company

Albireo, an Ipsen Company: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Gastroenterology, Other; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Odevixibat
Ileal bile acid transporter inhibitor
SLC10A2Phase 3Biliary Atresia; Alagille SyndromeFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05426733OdevixibatPhase 3Biliary AtresiaGastroenterologyOct 2026
NCT05035030OdevixibatPhase 3Alagille SyndromeOtherFeb 2027

From the company's SEC filings

Complete response letters from FDA

Targets

SLC10A2 (1)

Companies with the same targets

Mirum Pharmaceuticals GSK

Companies built like this

Dr. F. Köhler Chemie GRIN Therapeutics Mirum Pharmaceuticals Getz Pharma Huons Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.